Cell Transplantation for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (Cpvt)
Cell Transplantation for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (Cpvt)
Elham Zendedel,1,*Shiva Asadpour,2
1. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran 2. Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran
Introduction: Background: A method in which cells are used to repair or replace damaged tissues or cells is known as cell transplantation. Different types of cells may be used in the treatment of a number of diseases and disorders, according to emerging technologies. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited genetic disorder a condition in which the heart beats irregularly (arrhythmia).
Literature review: Scientists can investigate Ca2+ signaling parameters from human induced pluripotent stem cells (hiPSC-CMs) from healthy polymorphic ventricular tachycardia and aminergic catechol (CPVT1) that individuals have a new mutation p.F2483I on ryanodine receptors by differentiating cardiomyocytes from induced pluripotent stem cells (iPS-CM) (RyR2).
Conclusion: Despite the fact that iPSC-CMs offer a lot of promise as a treatment for CPVT, immunological rejection caused by HLA mismatching is a problem, hence additional research is needed.
Methods: Background: A method in which cells are used to repair or replace damaged tissues or cells is known as cell transplantation. Different types of cells may be used in the treatment of a number of diseases and disorders, according to emerging technologies. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited genetic disorder a condition in which the heart beats irregularly (arrhythmia).
Literature review: Scientists can investigate Ca2+ signaling parameters from human induced pluripotent stem cells (hiPSC-CMs) from healthy polymorphic ventricular tachycardia and aminergic catechol (CPVT1) that individuals have a new mutation p.F2483I on ryanodine receptors by differentiating cardiomyocytes from induced pluripotent stem cells (iPS-CM) (RyR2).
Conclusion: Despite the fact that iPSC-CMs offer a lot of promise as a treatment for CPVT, immunological rejection caused by HLA mismatching is a problem, hence additional research is needed.
Results: Background: A method in which cells are used to repair or replace damaged tissues or cells is known as cell transplantation. Different types of cells may be used in the treatment of a number of diseases and disorders, according to emerging technologies. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited genetic disorder a condition in which the heart beats irregularly (arrhythmia).
Literature review: Scientists can investigate Ca2+ signaling parameters from human induced pluripotent stem cells (hiPSC-CMs) from healthy polymorphic ventricular tachycardia and aminergic catechol (CPVT1) that individuals have a new mutation p.F2483I on ryanodine receptors by differentiating cardiomyocytes from induced pluripotent stem cells (iPS-CM) (RyR2).
Conclusion: Despite the fact that iPSC-CMs offer a lot of promise as a treatment for CPVT, immunological rejection caused by HLA mismatching is a problem, hence additional research is needed.
Conclusion: Background: A method in which cells are used to repair or replace damaged tissues or cells is known as cell transplantation. Different types of cells may be used in the treatment of a number of diseases and disorders, according to emerging technologies. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited genetic disorder a condition in which the heart beats irregularly (arrhythmia).
Literature review: Scientists can investigate Ca2+ signaling parameters from human induced pluripotent stem cells (hiPSC-CMs) from healthy polymorphic ventricular tachycardia and aminergic catechol (CPVT1) that individuals have a new mutation p.F2483I on ryanodine receptors by differentiating cardiomyocytes from induced pluripotent stem cells (iPS-CM) (RyR2).
Conclusion: Despite the fact that iPSC-CMs offer a lot of promise as a treatment for CPVT, immunological rejection caused by HLA mismatching is a problem, hence additional research is needed.